Abstract 1570P
Background
New breast cancer (BC) cases in county regions, including rural areas, account for 33% of all BC cases annually in China. Women residing in county areas generally have lower economic income and educational levels compared to urban women, lacking the access to medical resources. We utilized real-world data to explore the factors and impacts of delayed presentation for BC patients (pts) in county areas.
Methods
CHASE001 (NCT05544123) was an observational, multicenter study assessing real-world treatment patterns among BC pts in county areas of China. Descriptive statistics reported patient intervals and demographics. Multivariate regression analyses (MVA) and rank-sum test were used to analyze factors and impacts associated with delayed presentation.
Results
This analysis included 2405 BC pts with pathological diagnosis from February 2001 to July 2023. The median time from symptom onset to the first presentation to a healthcare professional was 1.0 month (IQR 0.3-5.0). the proportion of delayed presentation (intervals≥3 months) was 28.4%. The median interval among pts with delayed presentation was 12.0 months (IQR 6.0, 24.0). MVA revealed that lower education levels (OR 1.37 [95% CI 1.13-1.67]; p=.002), lack of breast screening (OR 1.42 [95% CI 1.06-1.91]; p=.019), being farmers and unemployed (OR 1.36 [95% CI 1.01-1.83]; p=.045), and residing in county areas in western China (OR 1.71 [95% CI 1.38-2.12]; p<.001) were significantly associated with delayed presentation. The rank-sum test demonstrated that delayed presentation was linked with higher disease burden. The proportion of pts with delayed presentation diagnosed with stage III-IV (p<.001), tumor size≥2cm (p<.001), and more than three positive lymph nodes (p=.005) was significantly higher than those who sought timely care.
Conclusions
This analysis indicates that patient delays are influenced by social determinants of health. Lower socioeconomic status and education levels are risk factors for delayed presentation, and medical resources are unevenly distributed across regions. Therefore, promoting early presentation through advocacy, education, and policy should be prioritized, especially targeting socially deprived and less educated populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10